Assembly Biosciences (FRA:V7B) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences COGS-to-Revenue?

Assembly Biosciences's Cost of Goods Sold for the three months ended in Mar. 2024 was €0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was €5.32 Mil.

Assembly Biosciences's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Assembly Biosciences's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

Assembly Biosciences COGS-to-Revenue Historical Data

The historical data trend for Assembly Biosciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences COGS-to-Revenue Chart

Assembly Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

Assembly Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Assembly Biosciences COGS-to-Revenue Calculation

Assembly Biosciences's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	6.568
	=	0.00

Assembly Biosciences's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	5.322
	=	0.00

Assembly Biosciences (FRA:V7B) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Assembly Biosciences's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 5.322
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Assembly Biosciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Assembly Biosciences (FRA:V7B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ASMB:USA

Address

331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines